Sometimes innovation isn’t about tearing the system apart, it’s about finding a smarter way in. That’s the play Synchron just ran. While others are busy cutting into skulls chasing the dream of mind-machine fusion, Dr. Thomas J. Oxley slipped through the bloodstream and changed the rules. His endovascular brain computer interface, the Stentrode, rides the jugular straight to the motor cortex, no scalpels, no open brain, no theatrics. That move just scored $200M in a Series D led by Double Point Ventures, with ARCH Ventures, Khosla Ventures, and a $54M bet from the Australian National Reconstruction Fund. Australia helped build this tech, and now it’s investing to bring it home.
This round isn’t just fuel, it’s liftoff. Synchron’s bringing the world’s first minimally invasive BCI from the lab to the clinic, bridging neuroscience, AI, and medical device engineering with surgical simplicity. Real patients are already proving it works. ALS patients using thought alone to control iPads, send texts, even fire off tweets. The COMMAND trial in the U.S. and the SWITCH trial in Australia, 10 patients combined, showed zero device-related serious adverse events and stable brain signal fidelity over 12 months. In medicine, “zero” is a rare and powerful number.
Dr. Oxley, neurologist and inventor, leads the charge from Synchron’s Brooklyn HQ. Professor Nicholas Opie, co-founder and founding CTO, engineered the Stentrode’s neural scaffolding from the University of Melbourne’s Vascular Bionics Lab. Dr. Rahul Sharma, interventional cardiologist turned Stanford professor, brings the vascular precision that makes this all possible. Add Dr. Riki Banerjee, the current CTO who cut her teeth at Medtronic, and you’ve got a leadership squad that blends science and scale. When veterans like Andy Rasdal, former DexCom CEO, and Mark Brister, 38 yrs, 450+ patents, join in, you know commercialization isn’t a question of if, but when.
Then there’s the tech stack. Apple hardwired Synchron’s protocol directly into iOS, letting patients control an iPad or Vision Pro with thought alone. NVIDIA’s on deck too, powering Synchron’s Chiral AI model, the world’s 1st cognitive AI trained on real human brain data. Together, they’re turning thought into action faster than you can blink.
At a $1B valuation, this isn’t hype, it’s inevitability. Synchron turned blood vessels into data highways, giving people with paralysis a new kind of freedom. The $200M raise pushes them closer to FDA approval, commercial launch, and a world where thought becomes movement. What Neuralink dreams in theory, Synchron’s already proving in practice.
